Expertise in
1
conditions

Jeng-yuan Hsu

Taitung, TNQ, TW 
Expertise in
1
conditions
Taitung, TNQ, TW 

Overview

Jeng-yuan Hsu practices practicing medicine in Taitung, Taiwan.

Hsu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Asthma, Stridor, and Gastroesophageal Reflux Disease (GERD).

They are actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 1 clinical trial.

Locations

Taitung, TNQ, Taiwan
Other Locations
TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3

44 Total Publications

Correction: Cheng et al. NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. Biomedicines 2022, 10, 2362.
Correction: Cheng et al. NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. Biomedicines 2022, 10, 2362.
Journal: Biomedicines
Published: January 09, 2025

Frequently Asked Questions about Jeng-yuan Hsu

Is Jeng-yuan Hsu a top-rated expert for Chronic Obstructive Pulmonary Disease (COPD)?

MediFind is an objective health platform that identifies experts based on real-world data. Jeng-yuan Hsu is classified as an Advanced expert for Chronic Obstructive Pulmonary Disease (COPD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jeng-yuan Hsu participate in research or clinical trials?

Yes. Jeng-yuan Hsu has published 44 articles and abstracts on conditions like Chronic Obstructive Pulmonary Disease (COPD). You can view a list of Jeng-yuan Hsu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsu's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile